Nanomedicines Based on Responsive Nanocarriers for Cancer Therapy

Advanced Therapeutics, Год журнала: 2023, Номер 7(2)

Опубликована: Сен. 26, 2023

Abstract Nanotechnology has been widely used in drug design recent years, showing great potential and advantages tumor therapy. However, the application of most traditional nanomedicines is still limited by low loading rate, poor targeting ability, systemic toxicity. Based on characteristics microenvironments, numerous studies indicate that construction stimuli‐responsive nanocarriers can effectively solve above problems improving delivery efficiency, reducing side effects, enhancing targeting. A significant feature responsive they release activate drugs at specific sites under stimulus, including internal stimuli (e.g., pH, reactive oxygen species (ROS), glutathione (GSH), enzyme, hypoxia, adenosine‐triphosphate (ATP), etc.) external light, thermo, ultrasound, etc.). Of note, learning about various pathways responses enable researchers to for Herein, this review focuses strategies In addition, role synergistic therapy also discussed. The expectation provide ideas practical effective nanocarriers.

Язык: Английский

---

Lipid-Conjugated Reduced Haloperidol in Association with Glucose-Based Nanospheres: A Strategy for Glioma Treatment

Molecular Pharmaceutics, Год журнала: 2024, Номер unknown

Опубликована: Сен. 20, 2024

Aggressive glioma exhibits a poor survival rate. Increased tumor aggression is linked to both cells and tumor-associated macrophages (TAMs), which induce pro-aggression, invasion, metastasis. Imperatively, for effective treatment, it important target TAMs. Haloperidol, neuropsychotic drug, avidly targets the sigma receptor (SR), expressed in higher levels cell types. Herein, we present development of novel cationic lipid-conjugated reduced haloperidol (±RHPC8), aims mediate SR-targeted antiglioma effect. Hypothetically, ±RHPC8 would act simultaneously as an SR-targeting ligand anticancer agent. As blood-brain barrier (BBB) obstructs direct targeting situ glioma, used BBB-crossing glucose-based carbon nanospheres (CSPs) deliver within tumor-bearing mouse brain. The resultant ±RHPC8-CSP nanoconjugate targeted SR-expressing cells. In orthotopic subcutaneous models, prolonged regressed tumors compared other treated groups. Notably, was significantly taken up by TAMs thus resulting macrophage polarization from M2 M1, exhibited markedly expression immunosuppressive cytokines released TAMs, including TGF-β, IL-10, VEGF. conclusion, designed presented nanodrug delivery system brain cancer treatment.

Язык: Английский

---

Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma

Assay and Drug Development Technologies, Год журнала: 2024, Номер 22(2), С. 73 - 85

Опубликована: Янв. 9, 2024

Glioblastoma, commonly known as glioblastoma multiforme (GBM), is one of the deadliest and most invasive types brain cancer. Two factors account for majority treatment limitations GBM. First, presence blood–brain barrier (BBB) renders malignancy ineffective, leading to recurrence without full recovery. Second, several adverse effects are associated with drugs used in conventional GBM treatment. Recent studies have developed nanocarrier systems, such liposomes, polymeric micelles, dendrimers, nanosuspensions, nanoemulsions, nanostructured lipid carriers, solid nanocarriers, metal particles, silica nanoparticles, which allow drug-loaded formulations penetrate BBB more effectively. This has opened up new possibilities overcoming therapy issues. Extensive methodical searches databases PubMed, Science Direct, Google Scholar, others were conducted gather relevant literature this work, using precise keyword combinations "GBM," "brain tumor," "nanocarriers." review provides deep insights into administration nanocarriers management explores advancements nanotechnology. It also highlights how scientific developments can be explained connection hopeful findings about potential future successful

Язык: Английский

---

Doxorubicin induces deglycosylation of cancer cell‐intrinsic PD‐1 by NGLY1

FEBS Letters, Год журнала: 2024, Номер 598(12), С. 1543 - 1553

Опубликована: Май 23, 2024

Tumor cells can express the immune checkpoint protein programmed death‐1 (PD‐1), but how cancer cell‐intrinsic PD‐1 is regulated in response to cellular stresses remains largely unknown. Here, we uncover a unique mechanism by which chemotherapy drug doxorubicin (Dox) regulates PD‐1. Dox upregulates mRNA while reducing levels tumor cells. Although shortens half‐life, it fails directly induce degradation. Instead, observe that promotes interaction between peptide‐ N (4)‐( ‐acetyl‐beta‐glucosaminyl)asparagine amidase (NGLY1) and PD‐1, facilitating NGLY1‐mediated deglycosylation destabilization. The maintenance of sensitizes Dox‐mediated antiproliferative effects. Our study unveils regulatory highlights potential role antitumor

Язык: Английский

---

Self-shrinking supramolecular nanoparticles syndicate energy suppression and NIR-II mild photothermal amplification of mitochondrial oxidative stress for breast cancer therapy

Nano Research, Год журнала: 2023, Номер 17(5), С. 4314 - 4328

Опубликована: Дек. 2, 2023

Язык: Английский

---